# Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)

> **NCT05861102** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 265 (actual)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** Jaktinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05861102
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-20
- **Primary completion:** 2026-05
- **Final completion:** 2026-07
- **Target enrollment:** 265 (ACTUAL)
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05861102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05861102, "Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05861102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*